

Promotion of Research & Innovation in Pharma-MedTech Sector (PRIP) Scheme

October 3, 2025 • vajiramandravi.com



PRIP (Promotion of Research and Innovation in Pharma MedTech Sector) Scheme Latest News

The government recently invited applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector scheme to make it a globally competitive and innovation-driven sector.

About PRIP Scheme

- The PRIP scheme was launched by the **Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers**, to transform India into a global powerhouse for R&D in the Pharma MedTech sector.
- The scheme was notified on August 17, **2023** with total **financial outlay of ₹5000 crores**.
- The aim of the scheme is to **promote industry-academia linkage for R&D** in priority areas and to inculcate the culture of quality research and nurture our pool of scientists.
- It focuses on **two components**:

- **Component A:**
 - Strengthening research infrastructure through **establishment of Centres of Excellence (CoE) in the seven existing National Institutes of Pharmaceutical Education and Research (NIPERs).**
 - These CoEs would be set up in **pre identified areas** with a **financial outlay of Rs 700 Crores.**
- **Component B:**
 - Promoting research in the pharmaceutical sector by **encouraging research in six priority areas** wherein **financial assistance** will be provided **for the industries, MSMEs, SMEs, startups working with government institutes, and for both in- house and academic research.**
 - The component has a financial outlay of **Rs.4250 Crores.**
 - **Bigger companies can seek funding of up to ₹125 crore, while startups can secure up to ₹1 crore** over a period of five years, based on their milestones.
- **Priority Areas:**
 - **New Chemical Entity, New Biological Entity, and Phyto-pharmaceuticals**
 - Complex **generics and Biosimilars**
 - **Precision medicine** (Targeted innovative therapeutics)
 - **Medical devices**
 - **Orphan Drugs**
 - Drug development for **anti-microbial resistance (AMR)**
- An **Empowered Committee under the chairmanship of CEO, NITI Aayog**, with the secretary-level representation of Pharmaceuticals, Health, ICMR, DBT, CSIR, AYUSH, and DST, **will provide guidance for the implementation** of the scheme.

Source: ET

Source: <https://vajiramandravi.com/current-affairs/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme/>

© Vajiram & Ravi. For personal use only.